Studies

OBJECTIVES: We hypothesized that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and treatment currently U.S. Food and Drug Administration (FDA) approved to reduce worsening of kidney disease and kidney failure may protect against…

Familial partial lipodystrophy (FPLD) is a rare genetic disorder leading to adipose tissue deficiency/redistribution and metabolic dysregulation with insulin resistance, diabetes mellitus, and dyslipidemia. Coincidence of FPLD and autoantibody-positi…

The role of insulin-like growth factor-binding proteins (IGFBPs) in the regulation of carbohydrate metabolism and the development of complications is well established; however, the impact of the glucagon-like peptide-1 receptor agonist semaglutide on…

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in type 2 diabetes (T2D) management for their glycemic and weight benefits. However, their appetite-suppressing effects may influence dietary intake and nutrient adequacy, yet…

BACKGROUND: Obesity is a major public health issue associated with significant humanistic and economic burden. In Greece, liraglutide 3.0 mg is currently the only reimbursed pharmacotherapy for obesity, restricted to patients with morbid obesity and…

INTRODUCTION: The PIONEER REAL India study assessed the effectiveness of oral semaglutide in adults with type 2 diabetes (T2D). METHODS: This was a 34-44-week, multicenter, non-interventional study in participants who had not previously received inje…

BACKGROUND: Obesity is a growing global health crisis. Clinical trials have found high-dose semaglutide to be a promising medication for weight loss, but real-world effectiveness data is limited. OBJECTIVE: In this study we assessed weight loss outco…

INTRODUCTION: Obesity is a chronic and relapsing disease and metabolic and bariatric surgery (MBS) provides the greatest weight loss efficacy to improve obesity related complications. However, weight recurrence and suboptimal weight loss occur in som…

Although transplantation remains the treatment of choice for end-stage renal disease, patients suffering from severe obesity are too often unlisted for this reason. Pre-transplant bariatric surgery is not free of risk and the use of 'Glucagon Like Pe…

BACKGROUND: Incretin mimetics are increasingly used to manage diabetes and to support weight loss in people with obesity. However, their application in primary care settings by general practitioners (GPs) remains underexplored. AIM: This study aimed…

Glucagon-like peptide 1 receptor (GLP-1) agonists have been traditionally used in the treatment of type II diabetes. However, in recent times they have become a cornerstone in the pharmacological management of weight loss, and their use is increasing…

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been reported to improve cardiovascular outcomes, potentially through glucose metabolism-independent mechanisms. However, their mechanism of heart rhythm remains controversial. MET…

Bimagrumab is a monoclonal antibody that targets activin type II receptors, blocks myostatin and related proteins: it promotes muscle growth and prevents muscle loss, while causing weight loss. It has been effective in sporadic inclusion body myositi…

OBJECTIVE: This study aims to identify the risk factors associated with gastrointestinal adverse events induced by semaglutide in patients with type 2 diabetes mellitus (T2DM) and to develop a predictive risk model. METHODS: A total of 215 patients w…

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasing in prevalence as the "go-to" medication for type 2 diabetes, obesity, and off-label weight loss. The changes associated with the use of these medications can result in an…

BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), improves metabolic health and reduces liver fat in people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease (MASLD). Whether changes in epigenet…